|
|
Volumn 62, Issue 2, 2015, Pages 492-493
|
|
Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
SORAFENIB;
BARCELONA CLINIC LIVER CANCER STAGING SYSTEM;
CANCER PATIENT;
CANCER PROGNOSIS;
CANCER STAGING;
CHEMOEMBOLIZATION;
COHORT ANALYSIS;
EUROPEAN;
HEPATITIS B VIRUS;
HONG KONG LIVER CANCER STAGING SYSTEM;
HUMAN;
LETTER;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
LIVER FIBROSIS;
LIVER RESECTION;
LIVER TRANSPLANTATION;
MULTIMODALITY CANCER THERAPY;
NONALCOHOLIC FATTY LIVER;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
RECEIVER OPERATING CHARACTERISTIC;
RISK FACTOR;
SURVIVAL RATE;
CARCINOMA, HEPATOCELLULAR;
DECISION SUPPORT SYSTEM;
FEMALE;
LIVER NEOPLASMS;
MALE;
PATHOLOGY;
PROCEDURES;
CARCINOMA, HEPATOCELLULAR;
DECISION SUPPORT TECHNIQUES;
FEMALE;
HUMANS;
LIVER NEOPLASMS;
MALE;
NEOPLASM STAGING;
|
|
EID: 84922228178
PISSN: 01688278
EISSN: 16000641
Source Type: Journal
DOI: 10.1016/j.jhep.2014.08.035 Document Type: Letter |
|
Times cited : (44)
|
|
References (5)
|
